When one size doesn’t fit all: aciclovir dosing and the obesity challenge
-
By
-
Maria Solovyeva
-
Calandra Feather
-
Nicholas Appelbaum
-
Elliott Gordon
-
June 17, 2026
-
Clinical Scorecard: Tailoring Aciclovir Dosage: Addressing the Challenges of Obesity in Pediatric Patients
At a Glance
| Category | Detail |
|---|
| Condition | Pediatric obesity and aciclovir dosing |
| Key Mechanisms | Weight-based and BSA-based dosing guidelines may lead to underdosing or toxicity due to differences in body composition. |
| Target Population | Pediatric patients, particularly those with obesity |
| Care Setting | Pediatric clinical practice |
Key Highlights
- Conventional dosing guidelines may not account for body composition differences in obese children.
- Pharmacovigilance data indicate significant treatment-related harm from aciclovir in pediatric patients.
- A proposed centile-sensitive model using AdjBW aims to improve dosing safety.
- Abrupt transitions in dosing regimens at age 12 can lead to significant dose drops.
- AdjBW-based dosing may mitigate overdosing at higher weight centiles.
Guideline-Based Recommendations
Diagnosis
- Consider obesity's impact on pharmacokinetics when prescribing aciclovir.
Management
- Use ideal body weight for children >98th percentile weight-for-age and sex for weight-based dosing.
Monitoring & Follow-up
- Monitor for adverse reactions, especially in patients with obesity.
Risks
- Potential for underdosing or toxicity due to inappropriate dosing calculations.
Patient & Prescribing Data
Pediatric patients aged 0-17 years, particularly those with obesity.
AdjBW may provide a more accurate dosing strategy compared to traditional methods.
Clinical Best Practices
- Consider using AdjBW for BSA calculations in obese pediatric patients.
- Evaluate dosing strategies to prevent abrupt transitions at age 12.
- Incorporate individual patient factors such as renal function and indication into dosing decisions.
Related Resources & Content
